Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Status changed: Signing up patients → Running, no new patients. Usually normal progress.

Spotted on Nov 9, 2026

Pushed back the final finish date by about 17 months: Jun 30, 2026 → Dec 2027.

Cellectis, a company that makes cell-based cancer treatments, pushed back the expected finish date of its UCART22 leukemia study from June 30, 2026 to December 2027, about 17 months later. Investors often watch for delays like this because they can hint that a study is running slower than planned, which may raise questions about when results will arrive. A date change like this also has ordinary explanations, such as scheduling adjustments or a steady pace of follow-up, and the company hasn't said why it moved, so on its own it doesn't prove anything about how the study is going.

AI-written from the facts above

Spotted on Nov 9, 2026

Moved the main results date slightly later: Jun 30, 2026 → Sep 16, 2026.

Spotted on Nov 9, 2026

Slightly lowered the number of patients, from 52 to 45.

Spotted on Nov 9, 2026

Changed the trial's main goal (what counts as success).

Cellectis changed what the UCART22 leukemia trial counts as success, adding a goal about how many patients get a complete response (the leukemia going into remission) on top of the earlier focus on safety and side effects. Investors often watch changes like this because a trial that adds or shifts its main goal can signal that the company is rethinking what it expects to show, which can point to worry about the original plan. The change can also have ordinary reasons, such as adding a measure that regulators or researchers asked for, so on its own it doesn't prove anything about how the drug is doing.